Last reviewed · How we verify
NCT05308719: NOTACS
Nasal Oxygen Therapy After Cardiac Surgery
NA trial testing High Flow Nasal Therapy in Cardiac Valve Disease in 1,280 participants. Completed in 6 December 2024.
6 December 2024
Quick facts
| Lead sponsor | Papworth Hospital NHS Foundation Trust |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | supportive care |
| Enrollment | 1,280 |
| Start date | 8 September 2020 |
| Primary completion | 6 December 2024 |
| Estimated completion | 6 December 2024 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- High Flow Nasal Therapy
Conditions studied
- Cardiac Valve Disease — all drugs for Cardiac Valve Disease →
- Coronary Artery Disease — all drugs for Coronary Artery Disease →
- Respiratory Failure — all drugs for Respiratory Failure →
Sponsor
Papworth Hospital NHS Foundation Trust
Who can join
18 and older, any sex, with Cardiac Valve Disease or Coronary Artery Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
NOTACS aims to determine if prophylactic use of high-flow nasal therapy (for a minimum of 16 hours after tracheal extubation, inclusive of up to one hour off randomised therapy for transfers around the hospital and/or physio mobilisation) increases days at home in the first 90 days after surgery, for adult patients undergoing cardiac surgery who are at high risk of postoperative pulmonary complications. The study also incorporates a health economic analysis to estimate the incremental cost-effectiveness and cost-utility of HFNT versus standard oxygen therapy at 90 days, from the view-point of the public sector, NHS and patients.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Recent innovations in adaptive trial designs: A review of design opportunities in translational research.
Kaizer AM, Belli HM, Ma Z, Nicklawsky AG, et al · · 2023 · cited 25× · PMID 37313381 · DOI 10.1017/cts.2023.537
Verify or expand the search:
- PubMed search for NCT05308719
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of High Flow Nasal Therapy
Trials testing the same drug.
- NCT05384275 — High-Flow Aerosol Generation Study · NA · completed
- NCT04655638 — HFNT vs. COT in COVID-19 · NA · completed
Other recruiting trials for Cardiac Valve Disease
Currently open trials in the same condition.
- NCT06247358 — Frailty, Physical Capacity and Lung Function in Postoperative Cardiac Surgery Patients · recruiting
- NCT06336213 — Antibacterial Tactics Based on Presepsin Level in Thoracic Aorta Surgery Patients · NA · recruiting
- NCT05002543 — CORCYM Mitral, Aortic aNd Tricuspid Post-maRket Study in a reAl-world Setting · recruiting
- NCT05506293 — European Multicentre Registry of Percutaneous Paravalvular Leak Closure · recruiting
Other Papworth Hospital NHS Foundation Trust trials
Trials by the same sponsor.
- NCT07289100 — Novel Sensors and Artificial Intelligence for Detection of Acute Pulmonary Exacerbations in Cystic Fibrosis and Bronchie · recruiting
- NCT06433960 — Radial Artery Assessment in Surgical Coronary Revascularisation · completed
- NCT05775263 — Validation of UK Protocols to Exclude Brain Blood Flow During Normothermic Regional Perfusion (NRP) · unknown
- NCT06421792 — PrOtamIne doSing clOt imagiNg (POISON) Study · not yet recruiting
- NCT06072872 — Portable Continuous Positive Airways Pressure (CPAP) in Excessive Central Airway Collapse (ECAC) Study · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05308719 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Papworth Hospital NHS Foundation Trust
- Last refreshed: 29 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05308719.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing